Reuters logo
3 个月前
BRIEF-Teva and Active Biotech announce CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint
2017年5月5日 / 晚上6点17分 / 3 个月前

BRIEF-Teva and Active Biotech announce CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint

May 5 (Reuters) - Teva Pharmaceutical Industries Ltd :

* Teva and Active Biotech announce CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint

* Study shows secondary endpoint which measured change in brain volume compared to baseline was positive

* In study, secondary endpoints measuring time to confirmed disability progression at 6, 9 months did not reach significance

* "While we have no current plans to further pursue Laquinimod in RRMS, we are continuing to study it in two other trials"

* Teva continues to evaluate potential of Laquinimod in Primary Progressive MS and Huntington Disease Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below